Penumbra, Inc. (NYSE: PEN) reported Q2 EPS of $0.86, $0.03 better than the analyst estimate of $0.83. Revenue for the quarter came in at $339.5 million versus the consensus estimate of $327.77 million.

GUIDANCE:

Penumbra, Inc. sees FY2025 revenue of $1.355-1.37 billion, versus the consensus of $1.354 billion. Which represents 13% to 15% growth over 2024 revenue of $1 billion, 195 million. The Company maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels. The Company also maintains guidance for both gross margin and operating margin for full year 2025.

For earnings history and earnings-related data on Penumbra, Inc. (PEN) click here.